Different reliance on ER signalling for replication and disease heterogeneity

🔬 I’ll be at #ASCO25 to discuss the differential genomic landscape of ER-low vs ER+ and ER- m+ #breastcancer. Join the conversation at Poster Board 50 on 6/2/25, 9:00 AM–12:00 PM! #bcsm @danafarber.bsky.social @danafarbernews.bsky.social @ascocancer.bsky.social

www.asco.org/abstracts-pr...

Try and play with it. All the feedback will be welcomed by
@ascocancer.bsky.social and @newsfromgoogle.bsky.social
!

ASCO Guidelines Assistant is available to anyone with an ASCO account until June 8, 2025. After this date, use of this tool is an exclusive benefit for ASCO members.

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing The art of sequencing therapy in the management of breast cancer is a multifaceted challenge that demands the careful integration of clinical trial data, real-world evidence, and individualized patien...

🚨NEW @ascocancer.bsky.social #EduBook chapter:
@hoperugo.bsky.social, @stolaney1.bsky.social &
I unpack the most debated trial design issues in m+ #BreastCancer —suboptimal control arms, crossover challenges, post-progression tx, non-inferiority margins, patient selection. ➡️ shorturl.at/nZWdI #bcsm

In medio stat virtus

Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue Study finds dozens of journals that have hiked their fees and started churning out papers after being acquired by small, recently formed companies.

Scientific publishers are under siege by distant buyers, flipping journals to #OpenAccess and raising APCs.

@Nature article explains the game:

“Invasion of the ‘journal snatchers’: the firms that buy science publications and turn them rogue”

www.nature.com/articles/d41...

“Education is one of the few forces powerful enough to break the cycle of #poverty. It gives children born into hardship the tools to rewrite their story—and shape a future of their own making.”

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer.
🔓 pubmed.ncbi.nlm.nih.gov/40196378/
@ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among women worldwide. Artificial intelligence (AI) s…

www.sciencedirect.com/science/arti...
If your business model is still selling algorithms, please stop. The accuracy of models is limited in time and space. The pursuit of generalizability is misguided. AI should be local, iterative, reflective and reflexive.

A big thank you to #LeoCeli and @mitcriticaldata.bsky.social for their consistent support in our research on AI #bias and disparities in breast cancer-related subfields. 🙏🧠

-> Model accuracy is limited in time and space. AI should be local, iterative, reflective and reflexive. The business model should be assisting health systems with creating, maintaining, curating, evaluating their data pipeline, and most importantly, their "learning pipeline".

3.we also observed #gender imbalance among first and last authors (male predominance), with #affiliations predominantly from high-income regions.

2.nearly all patient cohorts originated from high- #income countries, with no representation from low-income settings.

1.despite a ~300% increase in #AI-related publications between these periods, we found that only 0-25% of studies reported #race / #ethnicity data, with the majority of patients identified as Caucasian.

In our latest study, we identified 264 studies on AI-powered #mammography interpretation for #breastcancer detection out of 5774 in the two-year periods 2017-2018 and 2022-2023:

"Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity" shorturl.at/Q7xFo .

From #immunotherapy (IO) failures to new strategies & biotech innovations in metastatic TNBC, to IO timing, chemo backbones, & novel approaches in the early stage. All this & more in our latest review on immune checkpoint inhibitors in #TNBC. shorturl.at/izpbe @dfcibreastonc.bsky.social

Great to stop by #USCAP25 this afternoon to support our team’s work using #MachineLearning to characterize the tumor microenvironment in post-surgical #TNBC specimens after neoadjuvant chemo. @dfcibreastonc.bsky.social @uscap.org

Shoddy commentaries—a quick and dirty route to higher impact numbers—are on the rise AI-generated content floods literature with poor-quality publications, casts doubt on metrics, Science and Retraction Watch investigation finds

AI-generated content floods literature with poor-quality publications, casts doubt on metrics,
@science.org and Retraction Watch investigation finds.

www.science.org/content/arti...

Merry Christmas to all. Health truly is our most precious gift - It’s not just a cliché. For some, this season means remembering a loved one, facing a tough diagnosis, starting a new treatment, or getting difficult scan results. My heart is with you. ❤️

Breakthrough law offers cancer patients in New York relief for 'scalp-cooling therapy' New York has become the first state in the country to require insurance coverage for what's called "scalp-cooling therapy," which can reduce hair loss for chemo patients.

🚨 NY Gov. Kathy Hochul signs bill mandating private insurers cover scalp cooling systems starting Jan 1, 2026. 👏 First state to do so—hopefully paving the way for universal access. #CancerCare #HealthEquity #bcsm

shorturl.at/AXNdm

Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression.

Biopsy remains critical.

#sabcs24 @oncbrothers.bsky.social

Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS

Results are alligned w/ other MammaPrint High 2 results

@oncoalert.bsky.social

Join us in Row 10 to see our poster on outcomes in HER2+ & TNBC pts treated with neoadjuvant tx!

Key findings:
✅ pCR linked to better outcomes
✅ 3-yr RFS/OS varied by cT, cN, & subtype at dx
✅ In RD pts, cT, cN, & subtype stayed prognostic, but not in pCR pts (few events)
#SABCS24 #bcsm

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social

Don’t miss #SABCS24 Clinical Controversies Session on: Omission of Axillary Staging in ER-Positive #BreastCancer - Implications on Adjuvant Therapies, where Dr. Elizabeth Mittendorf will discuss the current data.

Please join us for the poster session today at 12.30PM! Our work on patients who experienced recurrence on adjuvant abemaciclib is in Row 9, right in front of the exhibitors. We look forward to chatting with you! @sabcs.bsky.social @dfcibreastonc.bsky.social

Meet Chiara Corti, MD(@ccortimd.bsky.social)! She came to Dana-Farber from IEO and the Università degli Studi di Milano. Now a #DFCIAdvancedFellow her research focuses on optimizing #BreastCancer treatment via tumor & microenvironment profiling and leveraging AI to streamline clinical operations.

Biomarker analyses of KN-522 shows most markers (T-cell GEP, HRD, HER2 signaling, PTEN, TNBC subtype) were prognostic but not predictive

High TMB showed a signal for pembro benefit, but only in 8% of pts

Predictive biomarkers for ICI in early TNBC are urgently needed!

@oncoalert.bsky.social

Don’t miss tomorrow’s poster session, with a stellar team! Honored to present with
@dfcibreastonc.bsky.social #SABCS2024 @sabcs.bsky.social